InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,617.84
(
0.37%
)
US TECH 100
19,277.20
(
0.35%
)
Dow Jones
40,847.49
(
0.03%
)
Brent Oil
75.30
(
-1.90%
)
Bitcoin
59,935.42
(
1.57%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120316
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: 10nisman post# 65828

Thursday, 09/04/2008 12:09:52 PM

Thursday, September 04, 2008 12:09:52 PM

Post# of 252939
>IDIX (Reason for yesterday's advance??)<

That the 100mg dose of IDX899 works as monotherapy is excellent news for two reasons:

1. The lower the dose, the better the tolerability will be when IDX899 is added to a standard treatment backbone such as Truvada.

2. The reason mentioned by Genisi (#msg-31929218): a lower dose has a smaller footprint, which facilitates co-formulation into a single pill with Truvada.

--
Still, I don’t think today’s news re the 100mg dose is what drove the share price yesterday because the data reported today were fully expected, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up